Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has swung higher to the tune of almost 8%. Interestingly, Friday’s afterhours ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...